A 6-month, multicenter, randomized, open-label study of safety and efficacy of everolimus-based regimen versus calcineurin inhibitor-based regimen in maintenance liver transplant recipients

Trial Profile

A 6-month, multicenter, randomized, open-label study of safety and efficacy of everolimus-based regimen versus calcineurin inhibitor-based regimen in maintenance liver transplant recipients

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2015

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Adverse reactions; Registrational
  • Acronyms RESCUE
  • Sponsors Novartis
  • Most Recent Events

    • 01 Oct 2009 Results published in Liver Transplantation.
    • 18 Aug 2009 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
    • 03 Jun 2009 Results were reported at the American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top